{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:20:16Z","timestamp":1791249616236,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ctrv.2012.10.008","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T14:35:32Z","timestamp":1354718132000},"page":"632-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies"],"prefix":"10.1016","volume":"39","author":[{"given":"Marcin","family":"Okroj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.10.008_b0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00005-009-0047-4","article-title":"Complement: coming full circle","volume":"57","author":"Friec","year":"2009","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.ctrv.2012.10.008_b0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.carres.2006.02.017","article-title":"The pattern of glycosyl- and sulfotransferase activities in cancer cell lines: a predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans","volume":"341","author":"Chandrasekaran","year":"2006","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.ctrv.2012.10.008_b0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1749-6632.1986.tb46579.x","article-title":"Membrane alterations in cancer cells: the role of oxy radicals","volume":"488","author":"Galeotti","year":"1986","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2012.10.008_b0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1023\/B:CACO.0000036189.61607.52","article-title":"Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain)","volume":"15","author":"Cejas","year":"2004","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ctrv.2012.10.008_b0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00262-003-0479-3","article-title":"Identification of tumor antigens and T-cell epitopes, and its clinical application","volume":"53","author":"Paschen","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2012.10.008_b0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0008-8749(76)90011-3","article-title":"Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt\u2019s lymphoma and infectious mononucleosis","volume":"22","author":"Budzko","year":"1976","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1349-7006.1995.tb03038.x","article-title":"Mannose-binding protein recognizes glioma cells: in vitro analysis of complement activation on glioma cells via the lectin pathway","volume":"86","author":"Fujita","year":"1995","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.ctrv.2012.10.008_b0040","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1080\/00365520410005603","article-title":"Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer","volume":"39","author":"Ytting","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0045","first-page":"489","article-title":"Depressed classical complement pathway activities in chronic lymphocytic leukaemia","volume":"60","author":"Fust","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0050","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1126\/science.186.4162.454","article-title":"Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells","volume":"186","author":"Irie","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2012.10.008_b0055","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","article-title":"Complement resistance of tumor cells: basal and induced mechanisms","volume":"36","author":"Jurianz","year":"1999","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors","volume":"40","author":"Fishelson","year":"2003","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0065","first-page":"348","article-title":"Expression of messenger RNAs for complement inhibitors in human tissues and tumors","volume":"53","author":"Kumar","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.10.008_b0070","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molimm.2007.04.025","article-title":"Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors","volume":"45","author":"Okroj","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0075","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.4049\/jimmunol.164.11.6075","article-title":"Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1","volume":"164","author":"Junnikkala","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2249.2003.02066.x","article-title":"Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid","volume":"131","author":"Donin","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0085","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.1406","article-title":"K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement","volume":"93","author":"Jurianz","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.10.008_b0090","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/JVI.77.1.592-599.2003","article-title":"Complement regulation by Kaposi\u2019s sarcoma-associated herpesvirus ORF4 protein","volume":"77","author":"Spiller","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molimm.2006.06.018","article-title":"Kaposi\u2019s sarcoma-associated herpes virus complement control protein: KCP \u2013 complement inhibition and more","volume":"44","author":"Mark","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0100","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.2007.03339.x","article-title":"Complement activation and cytokine response by BioProtein, a bacterial single cell protein","volume":"148","author":"Sikkeland","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0110","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00262-009-0685-8","article-title":"Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack","volume":"58","author":"Okroj","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2012.10.008_b0115","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/01.CIR.96.1.326","article-title":"Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway","volume":"96","author":"Collard","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ctrv.2012.10.008_b0120","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0125","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0130","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1517\/14712598.5.12.1593","article-title":"Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs","volume":"5","author":"Gelderman","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2012.10.008_b0135","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0140","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2741\/3688","article-title":"Molecular mechanisms of the antitumor effects of anti-CD20 antibodies","volume":"16","author":"Winiarska","year":"2010","journal-title":"Front Biosci"},{"key":"10.1016\/j.ctrv.2012.10.008_b0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 expression and function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002510050412","article-title":"Mice carrying a CD20 gene disruption","volume":"48","author":"O\u2019Keefe","year":"1998","journal-title":"Immunogenetics"},{"key":"10.1016\/j.ctrv.2012.10.008_b0160","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/eji.1830160802","article-title":"Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes","volume":"16","author":"Tedder","year":"1986","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0165","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI40231","article-title":"CD20 deficiency in humans results in impaired T cell-independent antibody responses","volume":"120","author":"Kuijpers","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2012.10.008_b0170","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","article-title":"CD20-targeted therapy: the next generation of antibodies","volume":"47","author":"van Meerten","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0180","first-page":"2143","article-title":"Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells","volume":"119","author":"Ivanov","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2012.10.008_b0185","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","article-title":"Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway","volume":"119","author":"Honeychurch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0190","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S1470-2045(10)70210-2","article-title":"New drugs for aggressive B-cell and T-cell lymphomas","volume":"11","author":"Murawski","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0195","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2007-02-074716","article-title":"NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0200","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2009-01-200469","article-title":"Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0205","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity","volume":"12","author":"van Meerten","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.10.008_b0210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/intimm\/dxs048","article-title":"High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRIIIa polymorphism","volume":"24","author":"Mishima","year":"2012","journal-title":"Int Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0215","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2010-07-298356","article-title":"The future of anti-CD20 monoclonal antibodies: are we making progress?","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0220","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2012.10.008_b0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.ctrv.2012.10.008_b0230","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1158\/1078-0432.CCR-11-0647","article-title":"RILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia","volume":"17","author":"Ge","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.10.008_b0235","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0240","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0245","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00262-010-0844-y","article-title":"Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen","volume":"59","author":"Bluemel","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2012.10.008_b0250","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/0161-5890(93)90155-5","article-title":"Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen","volume":"30","author":"Xia","year":"1993","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0255","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.4049\/jimmunol.174.9.5706","article-title":"Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity","volume":"174","author":"Ragupathi","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0260","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0265","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3816\/CLML.2010.n.069","article-title":"Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia","volume":"10","author":"O\u2019Brien","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ctrv.2012.10.008_b0270","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0275","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0280","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","article-title":"Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma","volume":"21","author":"Morschhauser","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0285","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood-2006-04-020057","article-title":"Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab","volume":"108","author":"Bowles","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0290","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0295","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0300","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1567-5769(00)00043-6","article-title":"Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases","volume":"1","author":"Miwa","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0305","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.molimm.2003.12.002","article-title":"Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?","volume":"40","author":"Blom","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0310","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-1759(89)90088-4","article-title":"Mouse strains with typical mammalian levels of complement activity","volume":"125","author":"Ong","year":"1989","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ctrv.2012.10.008_b0315","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0161-5890(95)00135-2","article-title":"Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity","volume":"33","author":"Ebanks","year":"1996","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0320","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0325","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma","volume":"156","author":"Barth","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0330","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-09-4109","article-title":"In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling","volume":"70","author":"de Haij","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.10.008_b0335","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2012.10.008_b0340","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0345","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3324\/haematol.2011.047159","article-title":"The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden","volume":"96","author":"Boross","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2012.10.008_b0350","doi-asserted-by":"crossref","first-page":"10562","DOI":"10.1158\/0008-5472.CAN-05-1894","article-title":"Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer","volume":"65","author":"Imai","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.10.008_b0355","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","article-title":"Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays","volume":"526","author":"Golay","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.ctrv.2012.10.008_b0360","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0365","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0370","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0375","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0380","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1073\/pnas.82.16.5470","article-title":"Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum","volume":"82","author":"Ramos","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.10.008_b0385","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0390","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/ijc.25560","article-title":"Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia","volume":"128","author":"Xu","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.10.008_b0395","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1749-6632.2009.04803.x","article-title":"Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement\/rituximab interactions & clinical results in refractory CLL","volume":"1173","author":"Klepfish","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2012.10.008_b0400","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2012.10.008_b0485","first-page":"196","article-title":"Investigation of the factors that influence complement-dependent cytotoxicity (CDC) following ofatumumab treatment in chronic lymphocytic leukaemia","volume":"137","author":"Middleton","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.ctrv.2012.10.008_b0410","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1073\/pnas.80.12.3816","article-title":"Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics","volume":"80","author":"Koski","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.10.008_b0415","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.molimm.2004.04.007","article-title":"Cell signals transduced by complement","volume":"41","author":"Bohana-Kashtan","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0420","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.cdd.4400627","article-title":"Complement mediated cell death is associated with DNA fragmentation","volume":"7","author":"Cragg","year":"2000","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ctrv.2012.10.008_b0425","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0430","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","article-title":"Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells","volume":"152","author":"Patz","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0435","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","article-title":"Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab","volume":"186","author":"Bologna","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0440","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00280-007-0638-x","article-title":"C-Jun-NH2-terminal kinase potentiates apoptotic cell death in response to carboplatin in B lymphoma cells","volume":"62","author":"Takada","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0445","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0450","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0455","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1158\/1078-0432.CCR-08-1536","article-title":"An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy","volume":"15","author":"Mishima","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.10.008_b0460","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.4049\/jimmunol.1103693","article-title":"Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients","volume":"188","author":"Beurskens","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2012.10.008_b0465","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00262-006-0260-5","article-title":"CD20-specific antibody-targeted chemotherapy of non-Hodgkin\u2019s B-cell lymphoma using calicheamicin-conjugated rituximab","volume":"56","author":"Dijoseph","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2012.10.008_b0470","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/ijc.23626","article-title":"Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels","volume":"123","author":"Stanglmaier","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.10.008_b0475","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2007-11-124487","article-title":"Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis","volume":"112","author":"Stolz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2012.10.008_b0480","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212002204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212002204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T23:33:16Z","timestamp":1595028796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737212002204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0305737212002204"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.10.008","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}